Curis, Inc. Stock price Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 8.35M | Sales 2025 * | 8.74M | Capitalization | 64.07M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -55M | EV / Sales 2024 * | 7.67 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.33 x |
P/E ratio 2024 * |
-1.79
x | P/E ratio 2025 * |
-2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.75% |
Latest transcript on Curis, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
Chief Tech/Sci/R&D Officer | - | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 03-10-31 | |
Chairman | 82 | 00-02-13 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |